A second look at the status quo for secondary acute myeloid leukemia after hypomethylating agents.

This editorial highlights the significant clinical challenges and poor outcomes faced by patients with secondary AML after prior hypomethylating agent therapy (HMA-sAML), underscoring the urgent need for novel treatments. The authors emphasize that current standard therapies remain inadequate, calling for clinical trials tailored specifically to address the unique biological complexity and therapeutic resistance observed in this patient population